Alnylam stock skyrockets on positive heart drug results

Shares of Alnylam Pharmaceuticals (ALNY) are jumping Monday morning after the company released positive results for its heart therapy medication, which was shown to reduce the risk of death from hospitalization by 28%.

Yahoo Finance Health Reporter Anjalee Khemlani joins Morning Brief to break down the latest developments from Alnylam and what it means for the pharmaceutical company moving forward.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Nicholas Jacobino

Video transcript

Tell us about the new study on al the lamb's drug.

I think I pronounced that correctly.

You're close, you're commercials for it yet to show me how to pronounce it.

So, yeah, I know.

I know.

So they have a hard drug, um, that helped cut the risk of death and hospitalization by 28%.

Uh, they had two different subgroups for this, which was interesting.

A part of the population of the clinical trial was already on another heart medication and then they had the ones that were just on this therapy alone and that, that group scored higher with a 33% reduction in the risk of death and heart uh, hospitalization.

So, really good news.

It's been closely watched.

It's one of those things where, uh, you know, the heart group and, uh heart disease we know is a big part of the broader, one of the biggest, uh, diseases and killers.

So this is really good news for that population.

Why can't they just make these drugs easier pronounce?

That's the real question here.

You know what?

I have a tiktok for you on that.

I don't know why I can't wait to see.

Yeah, we've come a long way since your user name.

Next time I gotta follow Angelika Mani.

Thanks so much for breaking it down for us.